New powerful treatment approach to type 2 diabetes
DOI: 10.32364/2587-6821-2021-5-9-592-597
A.M. Mkrtumyan1, M.I. Sviridova2
1A.S. Loginov Moscow Clinical Research Center, Moscow, Russian Federation
2N.E. Bauman City Clinical Hospital No. 29, Moscow, Russian Federation
The prevalence of type 2 diabetes (T2D) is very high and grows dangerously, being the most common cause of death. Severe vascular and neurological complications, which result in early disability and high mortality, and reduction in life expectancy and the quality of life, account for the medical and social relevance of T2D. T2D is characterized by progressive dysfunction of pancreatic β-cells in the development of insulin resistance. This paper addresses the mechanisms of action of glucose-lowering medications, i.e., pioglitazone belonging to a group of peroxisome proliferator-activated receptor (PPARγ) agonists, and alogliptin belonging to a group of dipeptidyl peptidase 4 (DPP-4) inhibitors. Pioglitazone increases insulin sensitivity via enhancing the expression of numerous genes encoding proteins that modulate glucose and lipid metabolism. Alogliptin improves the glucose-dependent activity of β-cells and inhibits the increased secretion of glucagon. Alogliptin is characterized by low risks of hypoglycemia and cardiovascular safety. Pioglitazone-alogliptin fixed-dose combination is helpful to control T2D effectively and safely since this combination affects 10 out of 11 pathophysiological defects resulting in T2D.
Keywords: type 2 diabetes, insulin resistance, β-cells, dipeptidyl peptidase 4 inhibitor, thiazolidinediones, gliptin.
For citation: Mkrtumyan A.M., Sviridova M.I. New powerful treatment approach to type 2 diabetes. Russian Medical Inquiry. 2021;5(9):592–597 (in Russ.). DOI: 10.32364/2587-6821-2021-5-9-592-597.
About the authors:
Ashot M. Mkrtumyan — Dr. Sc. (Med.), Professor, Head of the Division of Endocrine and Metabolic Disorders, A.S. Loginov Moscow Clinical Research Center; 86, Entuziastov road, Moscow, 111123, Russian Federation; ORCID iD 0000-0003-1316-5245.
Mariya I. Sviridova — C. Sc. (Med.), Head of the Center of Endocrine Disorders of Pregnancy, N.E. Bauman City Clinical Hospital No. 29; 2, Gospital’naya sq., Moscow, 111020, Russian Federation; ORCID iD 0000-0001-8942-3111.
Contact information: Ashot M. Mkrtumyan, e-mail: vagrashot@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 26.08.2021.
Revised 12.09.2021.
Accepted 30.09.2021.
2. Triplitt C., Cersosimo E., DeFronzo R.A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag. 2010;6:671–690. DOI: 10.2147/vhrm.s4852.
3. Scheen A.J. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(6):1005–1020. DOI: 10.1517/17425255.2015.1041499.
4. Hurren K.M., Dunham M.W. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opin Pharmacother. 2021;22(2):131–133. DOI: 10.1080/14656566.2020.1853100.
5. Console A., Formoso G. Do thiazolidinediones play a role in the treatment of type 2 diabetes mellitus? Diabetes Obesity Metab. 2013;15:967–977. DOI: 10.1111/dom.12101.
6. Di Pino A., DeFronzo R.A. Insulin resistanse and atherosclerosis implication for insulin-sensitising agents. Endocr Rev. 2019;40(6):1447–1467. DOI: 10.1210/er.2018-00141.
7. Eldor R., DeFronzo R.A., Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013;36 Suppl 2(Suppl 2):S162–S74. DOI: 10.2337/dcS13-2003.
8. Alam F., Islam M.A., Mohamed M. et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):5389. DOI: 10.1038/s41598-019-41854-2.
9. Pyörälä M., Miettinen X., Halonen P. et al. Insulin resistance syndrome makes it possible to predict the risk of coronary heart disease and stroke in healthy middle-aged men: the results of a 22-year follow-up of the Helsinki Police Study. Arterioscleris Thromb Vasc Biol. 2000;20:538–544. DOI: 10.1161/01.ATV.20.2.538.
10. Bonora E., Formentini G., Calcaterra F. et al. Insulin resistance according to HOME is an independent prognostic factor of cardiovascular diseases in patients with type 2 diabetes: prospective data from the Verona Study of Diabetic Complications. Diabetes Care. 2002;25:1135–1141. DOI: 10.2337/diacare.25.7.1135.
11. Dormandy J.A., Charbonnel D., Eckland D.J. et al. Secondary prevention of macrovascular events in patient with type 2 in the PROactive study (PROspective pioglitazone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet. 2005;366(9493):1279–1289. DOI: 10.1016/S0140-6736(05)67528-9.
12. Scherntaner J. Pleiotropic effects of thiazolidinediones on traditional and non — traditional risk factors for atherosclerosis. Int J Clin Pract. 2009;63:912–929. DOI: 10.1111/j.1742-1241.2009.02025.x.
13. Schernthaner G., Curry C.J., Scherntaner G.-H. Do we need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(Suppl 2):S155–S161. DOI: 10.2337/dcS13-2031.
14. Di Pino A., Defronzo R.A. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocrinologist. 2019;40(6):1447–1467. DOI: 10.1210/er.2018-00141.
15. Zhang Z., Zhang X., Korantzopoulous P. et al. The use of thiazolidinedione and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord. 2017;17:96–104. DOI: 10.1186/s12872-017-0531-4.
16. Daniele J., Abdul-gHani M., DeFronzo R.A. What are the options for pharmacotherapy for the treatment of prediabetes? Expert Opin Pharmacol. 2014;15:2003–2018. DOI: 10.1517/14656566.2014.944160.
17. DeFronzo R.A., Tripati D., Schwenke D.C. Pioglitazone for the prevention of diabetes with impaired glucose tolerance. New Engl J Med. 2011;364:1104–1115. DOI: 10.1056/NEJMoa1010949.
18. Zhou Y., Huang Y., Ji X. et al. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. DOI: 10.1210/clinem/dgz252.
19. Ahrén B., Foley J.E. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59(5):907–917. DOI: 10.1007/s00125-016-3899-2.
20. Van Raalte D.H., van Genugten R.E., Eliasson B. et al. The effect of alogliptin and pioglitazone combination on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170:565–574. DOI: 10.1530/EJE-13-0639.
21. Pratley R.E., Kipnes M.S., Fleck P.R. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167–176. DOI: 10.1111/j.1463-1326.2008.01016.x.
22. DeFronzo R.A., Fleck P.R., Wilson C.A. et al. Efficacy and safety of the dipeptidyl peptidase inhibitor alogliptin in patient with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317. DOI: 10.2337/dc08-1035.
23. Петунина Н.А., Кузина И.А., Тельнова М.Э. и др. Патофизиологически обоснованная комбинированная терапия алоглиптином и пиоглитазоном при сахарном диабете 2 типа. Эффективная фармакотерапия. 2021;17(20):6–12. DOI: 10.33978/2307-3586-2021-17-20-6-12.[Petunina N.A., Kuzina I.A., Telnova M.E. et al. Pathophysiologically Based Combination Therapy with Alogliptin and Pioglitazone in Type 2 Diabetes Mellitus. Effective Pharmacotherapy. 2021;17(20):6–12 (in Russ.)]. DOI: 10.33978/2307-3586-2021-17-20-6-12.
24. Eliasson B., Möller-Goede D., Eeg-Olofsson K. et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetology. 2012;55:915–925. DOI: 10.1007/s00125-011-2447-3.
25. White W.B., Cannon C.P., Heller S.R. et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335. DOI: 10.1056/NEJMoa1305889.
26. Shinji Kishimoto, Yoshihiko Kinoshita, Takeshi Matsumoto et al. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. Am J Hypertens. 2019;32(7):695–702. DOI: 10.1093/ajh/hpz065.
27. Rosenstock J., Inzucchi S.E. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–2408. DOI: 10.2337/dc10-0159.
28. DeFronzo R.A., Burant C.F., Fleck P. et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J Clin Endocrinol Metab. 2012;97(5):1615–1622. DOI: 10.1210/jc.2011-2243.
29. Van Raalte D.H., van Genugten R.E., Eliasson B. et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565–574. DOI: 10.1530/EJE-13-063.
30. Zannad F., Cannon C.P., Cushman W.C. et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. DOI: 10.1016/S0140-6736(14)62225-X.
31. Tomlinson B., Chan P., Wai Kei Lam C. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2021;1–14. DOI: 10.1080/14656566.2021.1985465 (Online ahead of print).
32. Ferreira J.P., Mehta C., Sharma A. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Med. 2020;18(1):165. DOI: 10.1186/s12916-020-01616-8.
33. White W.B., Heller S.R., Cannon C.P. et al. EXAMINE Investigators. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med. 2018;131(7):813–819.e5. DOI: 10.1016/j.amjmed.2018.02.023.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
